FDA Determines Regulatory Review Period for BELVIQ Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for BELVIQ, a human drug product, in response to patent extension applications submitted to the U.S. Patent and Trademark Office (USPTO)